Cargando…
Chapter 4 Picornavirus infections
The oldest member of the Picornaviruses group is polio virus, which was recognized early by clinicians because of its characteristic paralytic disease. This chapter examines the polio virus in regard to its virology, disease, and prevention by vaccines and chemoprophylaxis. Polio has been well contr...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134062/ https://www.ncbi.nlm.nih.gov/pubmed/32287579 http://dx.doi.org/10.1016/S0168-7069(08)70012-0 |
_version_ | 1783517757350871040 |
---|---|
collection | PubMed |
description | The oldest member of the Picornaviruses group is polio virus, which was recognized early by clinicians because of its characteristic paralytic disease. This chapter examines the polio virus in regard to its virology, disease, and prevention by vaccines and chemoprophylaxis. Polio has been well controlled in most developed countries using live or inactivated vaccines. Research work has intensified using genetic engineering techniques to produce live attenuated viruses with defined and stable mutations so as to prevent reversion to virulence, and also to produce immunogenic oligopeptides or proteins for a new generation of inactivated polio vaccines. Chemotherapy is therefore not required for polio infections. In contrast, neither vaccines have been developed against rhinovirus infections, nor are the vaccines thought to have a use, unless broadly reacting antigenic determinants can be located. Several interesting but only weakly effective antiviral compounds have been selected against rhinoviruses and this is a major research area at present. Studies continue also with interferon, but because of toxicity problems these look less interesting at present. Sequence and biochemical data is now available for several additional enterovirus strains and this could open new possibilities both with antivirals or vaccines (for example synthetic peptides) in the near future. |
format | Online Article Text |
id | pubmed-7134062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1985 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71340622020-04-08 Chapter 4 Picornavirus infections Perspect Med Virol Article The oldest member of the Picornaviruses group is polio virus, which was recognized early by clinicians because of its characteristic paralytic disease. This chapter examines the polio virus in regard to its virology, disease, and prevention by vaccines and chemoprophylaxis. Polio has been well controlled in most developed countries using live or inactivated vaccines. Research work has intensified using genetic engineering techniques to produce live attenuated viruses with defined and stable mutations so as to prevent reversion to virulence, and also to produce immunogenic oligopeptides or proteins for a new generation of inactivated polio vaccines. Chemotherapy is therefore not required for polio infections. In contrast, neither vaccines have been developed against rhinovirus infections, nor are the vaccines thought to have a use, unless broadly reacting antigenic determinants can be located. Several interesting but only weakly effective antiviral compounds have been selected against rhinoviruses and this is a major research area at present. Studies continue also with interferon, but because of toxicity problems these look less interesting at present. Sequence and biochemical data is now available for several additional enterovirus strains and this could open new possibilities both with antivirals or vaccines (for example synthetic peptides) in the near future. Published by Elsevier B.V. 1985 2008-05-29 /pmc/articles/PMC7134062/ /pubmed/32287579 http://dx.doi.org/10.1016/S0168-7069(08)70012-0 Text en © 1985 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chapter 4 Picornavirus infections |
title | Chapter 4 Picornavirus infections |
title_full | Chapter 4 Picornavirus infections |
title_fullStr | Chapter 4 Picornavirus infections |
title_full_unstemmed | Chapter 4 Picornavirus infections |
title_short | Chapter 4 Picornavirus infections |
title_sort | chapter 4 picornavirus infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134062/ https://www.ncbi.nlm.nih.gov/pubmed/32287579 http://dx.doi.org/10.1016/S0168-7069(08)70012-0 |